COVID-19 created opportunities for pharmaceutical companies to find new ways to engage with GPs. While face-to-face rep visits are likely to remain integral, it’s clear that increasingly time-poor GPs are seeking synthesised, relevant insights in a timely manner and want to drive the engagement on their terms.










